Autologous mesenchymal stem cells for secondary prog. MS
Posted: Tue Jan 17, 2012 11:58 am
This pilot study on 10 patients is from University of Cambridge, it echos the positive results from the Bristol University study on 6 patients. This study used bone-marrow-derived cells, not adipose. No immune system ablation was used. Results from 10 months after the infusion.
Title: Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study.
summry: This small but significant proof-of-concept study from the UK reports initial results following the intravenous administration of mesenchymal stem cells to ten people with secondary progressive MS. A dosing regimen based on body weight was used and no serious adverse events where reported following administration, though three people experienced mild, self limiting side effects.
The authors used paraclinical assessments of the visual pathway as clinical outcome measures and as a surrogate marker of wider disease. The results seem to suggest some structural, functional and physiological improvement after treatment in some visual endpoints which might be suggestive of neuroprotection.
source: Lancet Neurol. 2012 Jan 9. [Epub ahead of print]
study weblink: http://www.ncbi.nlm.nih.gov/pubmed/22236384
Title: Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study.
summry: This small but significant proof-of-concept study from the UK reports initial results following the intravenous administration of mesenchymal stem cells to ten people with secondary progressive MS. A dosing regimen based on body weight was used and no serious adverse events where reported following administration, though three people experienced mild, self limiting side effects.
The authors used paraclinical assessments of the visual pathway as clinical outcome measures and as a surrogate marker of wider disease. The results seem to suggest some structural, functional and physiological improvement after treatment in some visual endpoints which might be suggestive of neuroprotection.
source: Lancet Neurol. 2012 Jan 9. [Epub ahead of print]
study weblink: http://www.ncbi.nlm.nih.gov/pubmed/22236384